You are using an outdated browser. Please upgrade your browser to improve your experience and security.

Skip to content

SAVING WITH XELPROS

XELPROS is available to you even if you do not have insurance. Free home delivery, no copay cards or coupons required. You can purchase either a 1-month or 3-month supply of XELPROS.

$55 1-month supply
or
$110 3-month supply

Easy as 1-2-3 with XELPROS Xpress

our pharmacy partner

1. Our pharmacy partner will call

You will get a call from CapstanRx Pharmacy or Transition Pharmacy within 1 business day after they have received your prescription. You cannot get your XELPROS prescription without talking to the pharmacy first, so it is important to connect.

  • If you order your prescription through CapstanRx Pharmacy, they will call you from the phone number: 855-651-8360
  • If you order your prescription through Transition Pharmacy, they will call you from a 215 area code (Pennsylvania).
share your information

2. Share your information

You will be asked to verify your mailing address and payment method (credit card or check) by phone. No coupons are permitted for XELPROS, and XELPROS is not available through retail pharmacies.

home delivery

3. Receive your prescription in the mail

Our pharmacy partner will provide you with a tracking number, and your prescription will be delivered to your home in 3 to 5 business days or sooner.

  • Your signature is not required
  • XELPROS does not require refrigeration1

Please take the time to watch this short video that contains important information about XELPROS and XELPROS Xpress

Below you will find a downloadable PDF with more information for how you can access XELPROS

DOWNLOAD BROCHURE

INDICATIONS AND USAGE

XELPROS (latanoprost ophthalmic emulsion) 0.005% is a prescription medication for the treatment of high eye pressure (known as intraocular pressure, or IOP) in people with open-angle glaucoma or ocular hypertension.

IMPORTANT SAFETY INFORMATION

XELPROS is not recommended in patients with a known hypersensitivity to latanoprost, or any other ingredients in this product.

Some patients may experience darkening of the eye color, darkening of the eyelid and eyelashes, and increased growth and thickness of eyelashes while taking XELPROS. This darkening effect may increase as long as XELPROS is administered, and eye color changes are likely to be permanent. The increased growth and thickening of the eyelashes are reversible when XELPROS is discontinued.

Patients should avoid touching the tip of the dispensing container to the eye or surrounding areas during administration because this could cause the tip to become contaminated by common bacteria known to cause eye infections serious damage to the eye and subsequent loss of vision may result from using a contaminated product.

Contact lenses should be removed prior to the administration of XELPROS. Contact lenses can be reinserted 15 minutes following administration.

If more than one topical eye medication is used, the drugs should be administered at least 5 minutes apart.

The most common side effects of XELPROS may include eye pain/stinging, eye redness, eye discharge, growth of eyelashes, and eyelash thickening.

Patients who have eye surgery, develop an eye condition, or any other reaction while taking XELPROS should consult their eye doctor concerning the continued use of this product.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088

Please see the Full Prescribing Information.

References: 1. XELPROS™ [package insert]. Cranbury, NJ: Sun Pharmaceutical Industries, Inc; 2018

* 1 month = 1 bottle.

† You must buy a 3-month supply of XELPROS during a single purchase to receive it at this reduced price.

‡ In the event you elect the cash price for a covered drug during the benefit year (opt in), you agree to pay the cash price throughout the coverage year. The terms and conditions of this arrangement do not allow participants to submit any claim for reimbursement for the product purchased by any third-party Commercial payer, including Federal or State health care programs, nor include the amounts paid for the product in any submission for true out-of-pocket expenses calculations under a prescription drug plan.